Swedish biotech Alligator Bioscience (STO: ATORX) has entered into a research collaboration agreement has been signed with Professor Ignacio Melero of Spain’s Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain, to further investigate the biology of 4-1BB (CD137) as a target in cancer immunotherapy.
Alligator has two pipeline programs targeting 4-1BB, the fully owned monospecific antibody ATOR-1017, and the bispecific antibody ALG.APV-527, co-developed with Aptevo Therapeutics (Nasdaq: APVO).
Under the collaboration agreement, the team led by Prof Melero primarily will investigate the biological effects of 4-1BB activation in various pre-clinical cancer immunotherapy models. Prof Melero has acted as a scientific advisor and collaboration partner for Alligator since 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze